Nov 28, 2011
SuppreMol starts SM101 dosing in the context of SMILE study

Aug 02, 2011
SuppreMol employs Protagen biomarkers in SLE study

Jul 11, 2011
SuppreMol initiates Phase IIa clinical trial in Systemic Lupus Erythematosus (SLE) with its lead candidate SM101

January 9-11, 2012
Biotech Showcase 2012, San Francisco, CA, USA

January 9-12, 2012
30th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, USA

January 9-13, 2012
PEP TALK, San Diego, CA, USA

February 26-28, 2012
10th Annual BioPartnering North America, Vancouver, Canada

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol has developed a novel concept for the treatment of autoimmune diseases. Among these diseases, which are characterized by an immune response of the body against its own cells and tissues, are common illnesses such as Rheumatoid Arthritis (RA) or Multiple Sclerosis (MS) as well as orphan diseases such as Idiopathic Thrombocytopenic Purpura (ITP).

Many drugs against autoimmune diseases are trying to block the inflammatory processes that are the ultimate consequences of these diseases. As an alternative and more sustainable approach, SuppreMol has developed a way to combat autoimmune diseases upstream by blocking the activation of certain immune cells which are crucially involved in the onset of autoimmune diseases.

The activation of immune cells is modulated by their interaction with IgG antibodies that are bound to an antigen - the so-called immune complex. This binding of the IgG is mediated by the so-called Fc-region of the IgG, which attaches to Fcγ receptors on the cell surface.
Learn more about Fcγ receptors

In autoimmune diseases, antibodies specific for self-antigens (so-called auto-antibodies) recognize and bind to healthy tissue to form immune complexes which in turn lead to an immune response. This process leads to chronic inflammatory processes which are characteristic for auto-immune diseases. SuppreMol‘s therapeutic approach is based on the observation that these inflammatory processes are further boosted by the interaction of the immune complexes with specific receptors on the surface of immune cells.

Based on the long-standing expertise of its scientific founder, nobelist Robert Huber and his group, SuppreMol aims to modulate the activity of autoantibodies by substances competing with these cellular receptors, thereby hindering the autoantibodies from binding to them. As a result, the immune cells are downregulated and are unable to maintain the autoimmune response.
Learn more about SuppreMol‘s treatment approach